Cipla Enters Into Licensing Agreement With US Company For Key Covid Drug

Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients. (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)